The Domain-Specific and Temperature-Dependent Protein Misfolding Phenotype of Variant Medium-Chain acyl-CoA Dehydrogenase

The implementation of expanded newborn screening programs reduced mortality and morbidity in medium-chain acyl-CoA dehydrogenase deficiency (MCADD) caused by mutations in the ACADM gene. However, the disease is still potentially fatal. Missense induced MCADD is a protein misfolding disease with a molecular loss-of-function phenotype. Here we established a comprehensive experimental setup to analyze the structural consequences of eight ACADM missense mutations (p.Ala52Val, p.Tyr67His, p.Tyr158His, p.Arg206Cys, p.Asp266Gly, p.Lys329Glu, p.Arg334Lys, p.Arg413Ser) identified after newborn screening and linked the corresponding protein misfolding phenotype to the site of side-chain replacement with respect to the domain. With fever being the crucial risk factor for metabolic decompensation of patients with MCADD, special emphasis was put on the analysis of structural and functional derangements related to thermal stress. Based on protein conformation, thermal stability and kinetic stability, the molecular phenotype in MCADD depends on the structural region that is affected by missense-induced conformational changes with the central β-domain being particularly prone to structural derangement and destabilization. Since systematic classification of conformational derangements induced by ACADM mutations may be a helpful tool in assessing the clinical risk of patients, we scored the misfolding phenotype of the variants in comparison to p.Lys329Glu (K304E), the classical severe mutation, and p.Tyr67His (Y42H), discussed to be mild. Experiments assessing the impact of thermal stress revealed that mutations in the ACADM gene lower the temperature threshold at which MCAD loss-of-function occurs. Consequently, increased temperature as it occurs during intercurrent infections, significantly increases the risk of further conformational derangement and loss of function of the MCAD enzyme explaining the life-threatening clinical courses observed during fever episodes. Early and aggressive antipyretic treatment thus may be life-saving in patients suffering from MCADD.

[1]  S. Ferdinandusse,et al.  Correction: The Domain-Specific and Temperature-Dependent Protein Misfolding Phenotype of Variant Medium-Chain acyl-CoA Dehydrogenase , 2014, PLoS ONE.

[2]  B. Wilcken.  Newborn Screening: Gaps in the Evidence , 2013, Science.

[3]  A. Gerding,et al.  In vitro and in vivo consequences of variant medium-chain acyl-CoA dehydrogenase genotypes , 2013, Orphanet Journal of Rare Diseases.

[4]  D. Herebian,et al.  Functional Effects of Different Medium-Chain Acyl-CoA Dehydrogenase Genotypes and Identification of Asymptomatic Variants , 2012, PloS one.

[5]  R. Labaudinière,et al.  Tafamidis, a potent and selective transthyretin kinetic stabilizer that inhibits the amyloid cascade , 2012, Proceedings of the National Academy of Sciences.

[6]  H. Waterham,et al.  Risk stratification by residual enzyme activity after newborn screening for medium-chain acyl-CoA dehyrogenase deficiency: data from a cohort study , 2012, Orphanet Journal of Rare Diseases.

[7]  Shu-Chun Cheng,et al.  Differential domain structure stability of the severe acute respiratory syndrome coronavirus papain-like protease , 2012, Archives of Biochemistry and Biophysics.

[8]  N. Gregersen,et al.  Vulnerability to Oxidative Stress In Vitro in Pathophysiology of Mitochondrial Short-Chain Acyl-CoA Dehydrogenase Deficiency: Response to Antioxidants , 2011, PloS one.

[9]  H. Levy.  Newborn screening conditions: What we know, what we do not know, and how we will know it , 2010, Genetics in Medicine.

[10]  B. Andresen,et al.  A novel mutation of the ACADM gene (c.145C>G) associated with the common c.985A>G mutation on the other ACADM allele causes mild MCAD deficiency: a case report , 2010, Orphanet journal of rare diseases.

[11]  S. Waisbren,et al.  Sudden death in medium chain acyl-coenzyme a dehydrogenase deficiency (MCADD) despite newborn screening. , 2010, Molecular genetics and metabolism.

[12]  P. Rinaldo,et al.  Allelic diversity in MCAD deficiency: the biochemical classification of 54 variants identified during 5 years of ACADM sequencing. , 2010, Molecular genetics and metabolism.

[13]  H. Waterham,et al.  The enzymology of mitochondrial fatty acid beta-oxidation and its application to follow-up analysis of positive neonatal screening results , 2010, Journal of Inherited Metabolic Disease.

[14]  S. Fukuda,et al.  Effect of heat stress and bezafibrate on mitochondrial β-oxidation: Comparison between cultured cells from normal and mitochondrial fatty acid oxidation disorder children using in vitro probe acylcarnitine profiling assay , 2010, Brain and Development.

[15]  Matthew J. Nichols,et al.  Lack of genotype-phenotype correlations and outcome in MCAD deficiency diagnosed by newborn screening in New York State. , 2010, Molecular genetics and metabolism.

[16]  E. Mayatepek,et al.  A Novel Tandem Mass Spectrometry Method for Rapid Confirmation of Medium- and Very Long-Chain acyl-CoA Dehydrogenase Deficiency in Newborns , 2009, PloS one.

[17]  J. Vockley,et al.  Efficacy of sapropterin dihydrochloride in increasing phenylalanine tolerance in children with phenylketonuria: a phase III, randomized, double-blind, placebo-controlled study. , 2009, The Journal of pediatrics.

[18]  S. Gersting,et al.  Protein misfolding is the molecular mechanism underlying MCADD identified in newborn screening , 2009, Human molecular genetics.

[19]  P. Bross,et al.  Mitochondrial fatty acid oxidation defects—remaining challenges , 2008, Journal of Inherited Metabolic Disease.

[20]  A. Velázquez‐Campoy,et al.  Identification of pharmacological chaperones as potential therapeutic agents to treat phenylketonuria. , 2008, The Journal of clinical investigation.

[21]  S. Gersting,et al.  Loss of function in phenylketonuria is caused by impaired molecular motions and conformational instability. , 2008, American journal of human genetics.

[22]  Matthew J. Nichols,et al.  Novel mutations causing medium chain acyl‐CoA dehydrogenase deficiency: Under‐representation of the common c.985 A > G mutation in the New York state population , 2008, American journal of medical genetics. Part A.

[23]  F. Niesen,et al.  The use of differential scanning fluorimetry to detect ligand interactions that promote protein stability , 2007, Nature Protocols.

[24]  M. Khoury,et al.  The epidemiology of medium chain acyl-CoA dehydrogenase deficiency: An update , 2006, Genetics in Medicine.

[25]  Bernhard Liebl,et al.  Population spectrum of ACADM genotypes correlated to biochemical phenotypes in newborn screening for medium‐chain acyl‐CoA dehydrogenase deficiency , 2005, Human mutation.

[26]  P. Bross,et al.  The Y42H mutation in medium-chain acyl-CoA dehydrogenase, which is prevalent in babies identified by MS/MS-based newborn screening, is temperature sensitive. , 2004, European journal of biochemistry.

[27]  J. Vockley,et al.  Thermal unfolding of medium-chain acyl-CoA dehydrogenase and iso(3)valeryl-CoA dehydrogenase: study of the effect of genetic defects on enzyme stability. , 2004, Biochimica et biophysica acta.

[28]  Jung‐Ja P. Kim,et al.  Acyl-CoA dehydrogenases and acyl-CoA oxidases. Structural basis for mechanistic similarities and differences. , 2004, European journal of biochemistry.

[29]  Peter Bross,et al.  Genetic defects in fatty acid beta-oxidation and acyl-CoA dehydrogenases. Molecular pathogenesis and genotype-phenotype relationships. , 2004, European journal of biochemistry.

[30]  S. Ghisla,et al.  Acyl-CoA dehydrogenases. A mechanistic overview. , 2004, European journal of biochemistry.

[31]  A. Roscher,et al.  Tetrahydrobiopterin as an alternative treatment for mild phenylketonuria. , 2002, The New England journal of medicine.

[32]  S. Petersen,et al.  L-phenylalanine binding and domain organization in human phenylalanine hydroxylase: a differential scanning calorimetry study. , 2002, Biochemistry.

[33]  I Knudsen,et al.  Medium-chain acyl-CoA dehydrogenase (MCAD) mutations identified by MS/MS-based prospective screening of newborns differ from those observed in patients with clinical symptoms: identification and characterization of a new, prevalent mutation that results in mild MCAD deficiency. , 2001, American journal of human genetics.

[34]  R. Wanders,et al.  Molecular and functional characterisation of mild MCAD deficiency , 2001, Human Genetics.

[35]  P. Bross,et al.  Prevalent mutations in fatty acid oxidation disorders: diagnostic considerations , 2000, European Journal of Pediatrics.

[36]  J. Buchner,et al.  Structural Organization of Procaryotic and Eucaryotic Hsp90. INFLUENCE OF DIVALENT CATIONS ON STRUCTURE AND FUNCTION (*) , 1995, The Journal of Biological Chemistry.

[37]  M. Silink,et al.  Morbidity and mortality in medium chain acyl coenzyme A dehydrogenase deficiency. , 1994, Archives of disease in childhood.

[38]  C. Roe,et al.  Medium-chain acyl-coenzyme A dehydrogenase deficiency: clinical course in 120 affected children. , 1994, The Journal of pediatrics.

[39]  P. Bougnères,et al.  Déficit en déshydrogénase des acyl-CoA à chaîne moyenne: apport de la biologie moléculaire. , 1994 .

[40]  L. Bolund,et al.  Co-overexpression of bacterial GroESL chaperonins partly overcomes non-productive folding and tetramer assembly of E. coli-expressed human medium-chain acyl-CoA dehydrogenase (MCAD) carrying the prevalent disease-causing K304E mutation. , 1993, Biochimica et biophysica acta.

[41]  G. Böhm,et al.  Quantitative analysis of protein far UV circular dichroism spectra by neural networks. , 1992, Protein engineering.

[42]  K. Tanaka,et al.  Molecular survey of a prevalent mutation, 985A-to-G transition, and identification of five infrequent mutations in the medium-chain Acyl-CoA dehydrogenase (MCAD) gene in 55 patients with MCAD deficiency. , 1991, American journal of human genetics.

[43]  L. Bolund,et al.  Specific diagnosis of medium-chain acyl-CoA dehydrogenase (MCAD) deficiency in dried blood spots by a polymerase chain reaction (PCR) assay detecting a point-mutation (G985) in the MCAD gene. , 1991, Clinica chimica acta; international journal of clinical chemistry.

[44]  K. Tanaka,et al.  Molecular basis of medium chain acyl-coenzyme A dehydrogenase deficiency. An A to G transition at position 985 that causes a lysine-304 to glutamate substitution in the mature protein is the single prevalent mutation. , 1990, The Journal of clinical investigation.

[45]  D. Hale,et al.  An acyl-coenzyme A dehydrogenase assay utilizing the ferricenium ion. , 1990, Analytical biochemistry.

[46]  K. Tanaka,et al.  Molecular cloning and nucleotide sequence of cDNAs encoding the precursors of rat long chain acyl-coenzyme A, short chain acyl-coenzyme A, and isovaleryl-coenzyme A dehydrogenases. Sequence homology of four enzymes of the acyl-CoA dehydrogenase family. , 1989, The Journal of biological chemistry.

[47]  G. Lorimer,et al.  GroE heat-shock proteins promote assembly of foreign prokaryotic ribulose bisphosphate carboxylase oligomers in Escherichia coli , 1989, Nature.

[48]  L. Waddell,et al.  Medium-chain acyl-CoA dehydrogenase deficiency: genotype-biochemical phenotype correlations. , 2006, Molecular genetics and metabolism.

[49]  S. Ghisla,et al.  A mechanistic overview , 2004 .

[50]  S. Antonarakis.  Recommendations for a nomenclature system for human gene mutations , 1998 .

[51]  P. Bougnères,et al.  [Medium-chain acyl-CoA dehydrogenase deficiency: contribution of molecular biology]. , 1994, Archives de pediatrie : organe officiel de la Societe francaise de pediatrie.